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Available online 6 September 2014Abstract Preclinical research in animals often fails to adequately predict the outcomes observed in human patients.
Chimeric animals bearing individual human tissues have been developed to provide improved models of human-specific cellular
processes. Mice transplanted with human hematopoietic stem cells can be used to study human immune responses, infections
of blood cells and processes of hematopoiesis. Animals with humanized livers are useful for modeling hepatotropic infections as
well as drug metabolism and hepatotoxicity. However, many pathophysiologic processes involve both the liver and the
hematolymphoid system. Examples include hepatitis C/HIV co-infection, immune mediated liver diseases, liver injuries with
inflammation such as steatohepatitis and alcoholic liver disease.
We developed a robust protocol enabling the concurrent double-humanization of mice with mature hepatocytes and human
blood. Immune-deficient, fumarylacetoacetate hydrolase (Fah−/−), Rag2−/− and Il2rg−/− deficient animals on the NOD-strain
background (FRGN) were simultaneously co-transplanted with adult human hepatocytes and hematopoietic stem cells after
busulfan and Ad:uPA pre-conditioning. Four months after transplantation the average human liver repopulation exceeded 80%
and hematopoietic chimerism also was high (40–80% in bone marrow). Importantly, human macrophages (Kupffer cells) were
present in the chimeric livers.
Double-chimeric FRGN mice will serve as a new model for disease processes that involve interactions between hepatocytes and
hematolymphoid cells.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).animal models often fail to fully recapitulate humanIntroduction
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).processes. For this reason chimeric animals engrafted with
human cells and/or tissues play a very important role in
biomedical research, including stem cell biology. Xenograft-
ing of human cells began with tumor transplants and first
became possible when immune deficient strains of mice
became available (Rygaard and Povlsen, 1969). Currently,
many different kinds of primary cells can be permanently
engrafted in mice, among them hematopoietic stem cells,n access article under the CC BY-NC-ND license
Figure 1 Liver repopulation in FRG vs. FRGN mice. Blood levels
of human albumin are shown for male (M) and female (F) FRG and
FRGN mice on day 80 or day 120 after hepatocyte transplantation.
The dashed line shows the human albumin level (3.5 mg/mL)
indicating N80% liver humanization. The mean and standard
deviation are given by the black bars. The differences in albumin
levels between FRG and FRGNmice are highly significant at day 80
after transplantation (p = 2.86 × 10−22 for males and p = 6 × 10−5
for females).
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etic chimeras generated by human stem cell transplants
have been particularly important as they can be used to
study human immunological and inflammatory processes
in vivo (Greiner et al., 1998; Pearson et al., 2008; Shultz
et al., 2007). When blood stem cell transplantation is
combined with engraftment of thymic epithelium, signifi-
cant aspects of the cellular immune response can be
recapitulated.
The liver is the primary site of intermediary and xenobiotic
metabolism in mammals and has particular relevance for
pharmaceutical drug development. However, major differ-
ences exist in metabolic pathways between humans and
animals, especially the small rodents used extensively for
preclinical drug testing. Furthermore, many common human
infectious diseases are hepatotropic and cannot be modeled in
rodents. These include hepatitis B and C as well as malaria. To
overcome these limitations several mouse models with
humanized livers have been generated (Grompe and Strom,
2013). All of these models are based on hepatotoxic processes
in the mouse liver that generate a selective growth advantage
for transplanted human cells. Replacement indices of N90%
can be achieved (Azuma et al., 2007; Hasegawa et al., 2011;
Hu et al., 2013; Dandri et al., 2001; Tateno et al., 2004). Liver
chimeric mice have been used to study infections (Dandri et
al., 2001; Bissig et al., 2010; Mercer et al., 2001; Morosan et
al., 2006; Vaughan et al., 2012; Kawahara et al., 2013), drug
metabolism (Tanoue et al., 2013; Sanoh et al., 2012), gene
therapy (Lisowski et al., 2014) and hepatic stem cells (Duncan
et al., 2012; Takebe et al., 2013; Zhu et al., 2014).
Importantly however, many normal and pathophysiologic
processes in the liver involve interactions between blood
derived cells and hepatic epithelial cells. All liver infections
have a very important inflammatory component. In addition,
inflammation plays a substantial role in fatty liver disease
induced by alcohol or obesity and also has significant
effects on insulin resistance in type 2 diabetes. In addition
to the cellular immune system the liver resident macro-
phages, termed Kupffer cells, are involved in mediating
pathophysiologically important processes.
In order to better study interactions between human
hematolymphoid cells and hepatocytes two groups have
previously developed models that permit the simultaneous
engraftment of both hepatocytes and hematopoietic stem
cells. Washburn et al. used a mouse expressing a drug
inducible caspase 8 protein in the liver and were able to
engraft fetal hepatoblasts, hematopoietic progenitors and
thymus (Washburn et al., 2011). This model was used to
study immune responses and fibrosis induced by hepatitis
C. However, hepatic repopulation levels were low (~30%)
and the human liver epithelial cells were fetal in origin, not
displaying fully mature characteristics. More recently,
Gutti et al. reported a protocol for the generation of
double-chimeric mice using human cells of postnatal origin
(Gutti et al., 2014), i.e. cord blood stem cells and mature
hepatocytes. The recipient mouse was the uPA-SCID where
the selective advantage for human cells is based on
transgenic expression of urokinase plasminogen activator
(Dandri et al., 2001; Rhim et al., 1994). They compared
multiple approaches and generated double chimeras after
preconditioning with treosulfan (Gutti et al., 2014). While
the degree of hematopoietic chimerism was excellent, thereplacement index for hepatocytes was rather low. None of
the double-chimeric mice in their report achieved human
albumin levels above 1 mg/mL and therefore had repopu-
lation levels of b10%.
Unlike the uPA-SCID model the selection pressure for
human hepatocyte expansion can be controlled in immune
deficient mice lacking fumarylacetoacetate hydrolase (Fah).
Hepatotoxicity is blocked by administration of NTBC in the
drinking water or by a low tyrosine diet. Liver repopulation
levels of N90% can be routinely achieved in this model. Here
we describe a robust protocol in FRGN mice that can produce
mice with both N90% liver humanization and extensive
lymphohematopoietic chimerism. These dual chimeric mice
will serve as a platform for the study of interactions between
human hepatocytes and blood cells in vivo.Results
Generation of the FRGN strain
The non-obese diabetic (NOD) strain of mice has proven
ideal for the generation of human hematopoietic chimeras.
With an intact immune system these mice serve as a robust
model of autoimmunity mediated type1 diabetes (Kolb,
1987). On an immune deficient background, however, they
are the gold standard for human hematopoietic chimerism
(Shultz et al., 2007). The NOD/SCID/interleukin receptor
common γ-chain (Il2rg) knockout (NSG) mouse is used by
many laboratories (Ito et al., 2002). Polymorphisms at the
Sirp-α locus in NOD mice have been identified as the main
reason for the superior hematopoietic engraftment of this
strain (Takenaka et al., 2007). In order to create a strain
suitable for human hematopoietic engraftment as well as
liver humanization, we generated mice triply mutant in the
406 E.M. Wilson et al.Fah, Rag2 and the Il2rg genes (FRG mice (Azuma et al., 2007)
and genotyped offspring for the NOD Sirp-α allele. After four
generations of intercrossing, we obtained mice that were
homozygous for all four alleles and expanded this colony of
FRGN mice. Several large cohorts (n N 20 animals for each
genotype and gender) of FRG and FRGN mice were
transplanted with identical batches of human hepatocytes
in parallel (n = 4 transplantations) to determine whether the
NOD Sirp-α allele conferred an advantage for liver human-
ization. The overall survival rates during NTBC withdrawal
were similar between strains and were ~40% after 5 months
(data now shown). However, we observed several significant
differences between FRG and FRGN mice. First, complete
liver repopulation occurred more quickly in the FRGN strain,
especially in males. Human albumin levels were clearly
higher on day 80 after transplantation in FRGN mice as
compared to FRG animals transplanted at the same time
with the same batch of cells (Fig. 1). Importantly however,
more than 50% of mice of all strains and genders that
survived the NTBC withdrawal regimen had human blood
albumin levels N3.5 mg/mL four months after transplanta-
tion, indicating liver replacement levels of at least 80%.
Second, the average litter size was larger with an average
of nine per FRGN breeder vs. five pups for FRG breeders
(Suppl. Fig. 1). Finally, the average body weights of
8-week-old mice were higher in the FRGN strain for both
genders; 22.8 +/− 2.7 g vs. 17 +/− 1.7 g for females (p =
1.4 × 10−113) and 27 +/− 2.6 g vs. 22.2 +/− 2.2 g for males
(p = 6.7 × 10−54).
Development of a protocol for double chimerism
The engraftment of human hepatocytes is enhanced by
pre-administration of an adenoviral vector expressing
urokinase plasminogen activator (Ad:uPA) (Azuma et al.,
2007). Preconditioning of immune deficient mice with
human hematopoietic stem cells requires either prepara-
tive irradiation or the administration of a DNA-damaging
chemical. We sought to develop a protocol that would have
wide applicability in many laboratories and not depend
on the availability of a radiation source. For this reason
we chose to test busulfan, a widely available drug which
has previously been used for generating hematopoieticFigure 2 Schematic ofchimeras in both mice (Hayakawa et al., 2009) and humans
(Wilkinson et al., 2013; Hassan, 1999). We first performed a
dose–response curve to determine the maximum dose that
could be used in combination with the standard dose of
uPA-adenovirus in FRGN mice. We found that a single dose
of 30 mg/kg along with 1.25 × 109 pfu of Ad:uPA per 25 g of
body weight was the maximum dose tolerated with 100%
survival (data not shown).
We next applied this dosing regimen in the transplant
setting (Fig. 2). Two separate cohorts of weanling female
FRGN mice (n = 12 each, age 3 weeks) were transplanted
concurrently with standard doses of adult human hepato-
cytes (500,000) and CD34+ peripheral blood stem/progeni-
tor cells (200,000). The hepatocytes and blood stem cells
were from distinct donors and were not HLA or otherwise
matched. The hepatocytes and blood stem cells were mixed
and given intrasplenically. After transplantation, NTBC was
withdrawn to permit selection of the transplanted hepato-
cytes. Liver chimerism was monitored by serial measure-
ment of the levels of human albumin in blood and human
hematopoietic chimerism was estimated by FACS analysis of
peripheral blood. Overall survival of transplanted animals to
full liver repopulation was 11/24 = 46%.
Hematopoietic chimerism
Peripheral blood analysis 12–15 weeks after transplantation
indicated high levels of liver repopulation along with substan-
tial blood chimerism in all surviving animals (Table 1). We
therefore euthanized the animals and performed a detailed
analysis of hematopoietic tissues and liver. Blood lineages
were analyzed by FACS (see Suppl. Fig. 2, 3) and the liver was
subjected to FAH immunohistochemistry. Fig. 3 depicts the
overall distribution of human chimerism in spleen, bone
marrow and thymus. As shown in Fig. 3, human chimerism in
the spleen averaged ~60% with a range from 28 to 85%. Bone
marrow chimerism was ~50% and all animals had N90% human
cells in the thymus. These numbers are comparable to other
studies (Gutti et al., 2014), especially when adult peripheral
blood stem cells are used as donors. Human CD20 and CD10
expression was used to ascertain the percentages of mature B-
and Pre-B-cells respectively among the human cells. As
expected both lineages were found and mature B-cellsdual humanization.












1 9.2 ≥90 22 17
2 6.1 ≥90 13 17
3 6.2 ≥90 13 17
4 5.0 ≥90 13 19
5 5.5 ≥90 5 21
6 3.9 80–90 8 21
7 4.2 80–90 7 21
8 6.0 ≥90 6 21
9 4.4 80–90 5 21
Table 1: Results from nine FRGN female mice transplanted with human hepatocytes and human CD34+ cord blood stem cells at three weeks of
age. Human albumin (hAlb) blood levels of N3.5 mg/mL indicate liver humanization of N80% and N4.5 mg/mL represents N90%. These estimates
were validated by FAH immunohistochemistry at harvest (Fig. 4). Chimerism of the peripheral blood mononuclear cells (PBMC) was determined
between 17 and 21 weeks post transplant by flow cytometry for the human CD45 surface marker.
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ration (CD20/10) in bone marrow was closer to 1:1 (Fig. 3).
The thymus contained mostly T-cells and both CD4 and CD8
human T-cells were present as expected. Myeloid cells were
also found. In the bone marrow ~30% of the human cells were
positive for the monocyte marker CD64. 8–40% of CD45
positive human bone marrow cells expressed the myeloid
markers CD13 or C33. Thus, human hematopoietic cells of both
the lymphoid and myeloid lineages were present 4–5 months
after transplantation, indicating multilineage engraftment
indicative of the presence of human stem/progenitor cells.
Overall, the degree of hematopoietic chimerism and the
lineage distribution were in concordance with previous
publications using postnatal peripheral blood CD34+ cells for
transplantation (Brehm et al., 2014).Liver chimerism
In our model peripheral blood albumin levels of N3.5 mg/mL
correlate with overall replacement indices of N80% and
here all surviving animals reached at least this level. FAHFigure 3 Human hematopoietic chimerism. Scatter plots showing t
CD4 and CD8 in spleen, bone marrow and thymus of each double hum
human CD45 positive cells.immunohistochemistry (IHC) was used to measure the
degree of liver humanization (Fig. 4). Indeed, the liver
replacement index determined by this method exceeded
90% in all mice, confirming the peripheral blood albumin
measurements shown in Table 1. We next sought to deter-
mine whether human hematopoietic derivatives important
for liver biology could be detected. Kupffer cells are
essential to many hepatic functions and play a major role
in inflammatory responses in this organ (Ajakaiye et al.,
2011; Gregory and Wing, 2002; Roberts et al., 2007). CD68 is
considered a specific marker for activated Kupffer cells and
we therefore used two methods to determine whether
human CD68+ cells were present in our chimeras. First, we
performed RT-PCR with human-specific primers, not capable
of detecting mouse mRNA. As seen in Fig. 5, control RNA
from untransplanted FRGN mice had no human CD68 mRNA,
whereas double-chimeric mice and samples from human
liver explants did. Importantly, FRGN mice that had been
given only hepatocytes but not blood did not show any
detectable levels of CD68 transcript. We next performed IHC
using antibodies with specific reactivity for human proteins.
CD45 positive human cells could be seen throughout thehe percentages of human chimerism for CD45, CD20, CD10, CD3,
anized mouse. The values were calculated as a percentage of the
Figure 4 High degree of liver chimerism. Examples of Fah immunohistochemistry (green fluorescence). Nuclei are stained blue
with DAPI. A–D: double humanized mice; A = low magnification, stitched from multiple images, scale bar = 500 μm, B,C = 200×; D =
400×, B–D scale bar = 100 μm, Yellow triangles: human hepatocytes; White arrows: remnant mouse cells. The vast majority of
hepatocytes are Fah positive and therefore human. A–C display N95% and D ~80–90% humanization.
408 E.M. Wilson et al.double-chimeric livers (Fig. 6A). CD68 IHC confirmed the
RT-PCR results and activated Kupffer cells were found
throughout the parenchyma (Fig.6B). In addition, human T-
and B-cells were also found throughout the liver (Fig. 6) as
expected from the high degree of hematopoietic chimerism
in multiple organs.Figure 5 Double humanized liver express human CD68 mRNA. RT-P
Top panel (A): human CD68; bottom panel (B) = mouse GAPDH. A
humanized mice; 6 = untransplanted mouse; 7 = liver chimera only
human liver; 9 = primary human hepatocytes. Human CD68 mRNA (3
and cells isolated from human liver (8,9), but not in untransplan
hepatocytes (7). A larger band (641 bp) derived from the genomic
samples harvested from mice (1–7) had murine GAPDH and human lDiscussionThe FRGN dual chimerism system reported here is the first to
achieve both extensive liver humanization with mature
hepatocytes and concurrent hematopoietic engraftment inCR of liver from 5 double humanized mice and controls is shown.
rrows indicate the proper PCR product. Samples 1–5 = double
(no hematopoietic transplant); 8 non-parenchymal cells from
76 bp lower band) was expressed in all double-humanized mice
ted controls (6) or FRGN mice repopulated with only human
human CD68 gene was seen in the liver only chimeras (7). All
iver samples were negative as expected.
Figure 6 Human hematopoietic cells in the liver of double humanized mice. Immunohistochemistry was done to detect hematopoietic cells in the liver parenchyma (200×). The top
row (A–E) depicts liver from a double-chimeric mouse and the bottom row shows liver from a human hepatocyte-only chimera (F–J). Mouse macrophages stained with F4/80 were
present in both animals (E,J). However, staining with human-specific antibodies to CD45 (A,F), CD68 (B,G), CD20 (C,H) and CD3 (D,I) showed that only double-humanized livers
















410 E.M. Wilson et al.the same animals. Previously reported models of human
liver/blood dual chimerism in mice achieved robust hema-
topoietic engraftment (Washburn et al., 2011; Gutti et al.,
2014; Bility et al., 2012). However, the degree of liver
repopulation achieved was low. While low hepatocyte
replacement indices can support some human liver infec-
tions, particularly hepatitis B, a high degree of liver
chimerism is essential for any study that involves physiologic
or xenobiotic metabolism, pharmacokinetics, drug–drug
interactions, transport or toxicology. The precise threshold
for each of these applications varies, but generally liver
humanization levels of N70% are needed and “more is
better” (Grompe and Strom, 2013). In addition, it is im-
portant that the human hepatocytes are of postnatal origin
and fully mature. Mature human hepatocyte functions in
chimeric FRGN mice have been demonstrated by analysis of
their gene expression showing absence of fetal markers
(Azuma et al., 2007), cytochrome p450 induction (Azuma
et al., 2007; Strom et al., 2010), bile acid and lipoprotein
metabolism (Ellis et al., 2013). The immature fetal liver
cells used by Washburn et al. (2011) lack some critical
features of adult drug metabolism. Our overall success rate
of double humanization was ~50% of transplanted animals,
making the protocol robust enough for the generation of
large cohorts of experimental animals.
The FRGN strain developed herein is suitable for hema-
topoietic reconstitution and in addition to this has some
other advantages over our originally reported FRG KO on
the C57BL6 strain (Azuma et al., 2007). While the final
percentages of highly reconstituted (N80%) mice did not
differ significantly between the strains, FRGN mice achieved
maximal liver humanization significantly faster. It is inter-
esting that the result parallels those from hematopoietic
xenotransplantation and suggests that the interaction
between Sirp-α on mouse macrophages and human CD47 on
hepatocytes is important for engraftment, as it has been
shown for blood transplantation (Takenaka et al., 2007). Not
only do FRGN mice repopulate their livers more quickly, but
also their breeding efficiency is also higher and their body
weight is larger. It is of note that the FRGN strain used
herein had not yet been fully backcrossed onto the NOD
background and still harbored some C57/BL6 genome. The
colony is currently being fully inbred and it is possible that
further improvements will result from having completely
congenic FRG-NOD strain.
None of the many potential applications of liver/blood
double chimeras was validated in this study. Instead, we
chose to focus on clearly documenting the degree of
chimerism that can be obtained. However, experiments
to study interactions between human inflammatory cells
and hepatocytes will now be possible in the future. It will
be particularly interesting to use our model for Hepatitis
C/HIV co-infection (Rockstroh and Spengler, 2004) and
metabolically induced steatohepatitis (Kubes and Mehal,
2012), be it by ethanol or a high fat diet.
Thymic epithelium was not humanized in our current
generation double-chimeric FRGN mice thus limiting its
utility for studying human T-cell responses. For this reason
it will be desirable to generate tri-chimeric FRGNs in the
future, possibly by transplanting iPSC derived human
thymic epithelium (Parent et al., 2013) along with the
other tissues.Materials and methods
Materials
Busulfan (catalog # B2635) and dimethyl sulphoxide (DMSO,
catalog #D2650) were purchased from Sigma-Aldrich
Chemicals; non-platable human hepatocytes (N70% viable
by trypan blue staining) were purchased from Biorec-
lamationIVT (catalog# F00995); human frozen bone mar-
row CD34+ cells were purchased from AllCells (Catalog#
ABM017F); HCM media was purchased from Lonza (Catalog#
CC-3198 and CC-3199). The sources of antibodies used for
FACS and immunohistochemistry are given in Supplemental
Table 1. HBSS, fetal bovine serum and 4% paraformal-
dehyde were purchased from Fisher Scientific.
Bone marrow transplantation of FRG and
FRGN breeders
In order to avoid the complications of immune deficiency
during breeding, all breeder animals are transplanted as
weanlings (~3 weeks of age) by retro-orbital injection of one
million nucleated bone marrow cells from strain matched
immune proficient adult donor animals (C57/BL6 or NOD/
ShiLtJ, Jackson Laboratories). The transplanted animals are
set into breeding at six weeks of age.
Sirp-α genotyping assay
PCR is performed on genomic DNA using a three primer PCR.
The C57BL6 SIRP-α PCR product is 350 bp and the NOD SIRP-α
product is 180 bp in length.
Primer SIRP-α _ C57BL6 forward: 5′ AGGAGCCACGGGGA
AGGAACT 3′; SIRP- α NOD forward: 5′ CAACAGAACACTTTCC
TCGAGTTAC 3′; SIRP-α common reverse primer: 5′ AGACC
TCTGTTCCCCCTCCAGATTG 3′. The wild type SIRP-α PCR
product found in C57BL6 is 350 bp and the product found in
the NOD SIRP-α gene is 180 bp.
Dual humanization protocol
Weanling mice were transplanted after preconditioning
with both busulfan and a urokinase-expressing adenovirus
(Fig. 2).
Busulfan was dissolved in sterile DMSO at 50 mg/mL,
diluted to 2.25 mg/mL solution in sterile 0.9% saline and
delivered by intraperitoneal injection at 30 μg/g body
weight 24 h prior to transplantation. Ad:uPA (Azuma et
al., 2007; Vrancken Peeters et al., 1997) was diluted to
1.25 × 109 plaque forming units (pfu)/100 μL in sterile 0.9%
saline and filtered using an Acrodisc Syringe filter with
0.45 μ HT Tuffryn membrane. Each mouse was anesthe-
tized using isoflurane and given 5 × 107 pfu per gram of
body weight via retro-orbital vein injection 24 h before
transplantation.
Cryopreserved human hepatocytes were thawed and the
cryopreservation solution was removed by centrifugation at
100 ×g for 5 min at 4 °C followed by resuspension in HCM
media. The resuspended hepatocytes were diluted 1:1 in
0.4% trypan blue and the cell number and viability were
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centrifuged again at 100 ×g for 5 min at 4 °C and
reconstituted in HCM at 10 × 106 cells/mL.
Cryopreserved human bone marrow CD34+ cells were
thawed and the cryopreservation solution was removed by
centrifugation at 500 ×g for 10 min at 4 °C followed by
resuspension in HCM. The resuspended CD34+ HSC were
diluted 1:1 in 0.4% trypan blue and the cell number and
viability were determined using a hemocytometer. The bone
marrow CD34+ cells were centrifuged again at 500 ×g for
10 min at 4 °C and reconstituted in HCM at 4 × 106 cells/mL.
For cell injection, the mice were anesthetized using
isoflurane, the two cell types were mixed 1:1 and each
mouse received 500,000 hepatocytes and 200,000 bone
marrow CD34+ cells by intrasplenic injection as previously
described (Gutti et al., 2014; Rajvanshi et al., 1996;
Bumgardner et al., 1998). The mice were then subjected to
the standard NTBC withdrawal regimen (Azuma et al., 2007).
Human albumin ELISA
Starting at eight weeks post transplantation human albumin
levels are monitored using the Bethyl Laboratory Quantita-
tive Human Albumin ELISA Kit (Catalog #E90-134) according
to the manufacturer's protocol. Two microliters of whole
blood is collected via the saphenous vein and immediately
diluted into ELISA diluent buffer. Whole blood albumin
levels of N4 mg/mL correlate with repopulation indices
N90% (Azuma et al., 2007).
FACS analysis of tissues
The spleen and thymus were isolated. Each organ was
placed inside a 100 μm cell strainer on top a 50 mL conical
tube. Using the plunger end of a 5 mL syringe the tissues
were pulverized. The cells were collected in the 50 mL
tube by rinsing the plunger and strainer with 10 mL of HBSS
containing 3% fetal calf serum. The cells were pelleted by
centrifugation and any contaminating red blood cells were
lysed and removed by additional centrifugation. Between
4 × 105 and 1 × 106 viable cells were used for staining with
each antibody cocktail.
The femora and tibiae from both sides of the mouse were
isolated, opened at both ends and flushed with PBS using
a 27G needle attached to 1 cc syringe. The eluent was
collected in a 50 mL conical tube. The cells were pelleted
by centrifugation at 500 ×g for 10 min at 4 °C and any
contaminating red blood cells were lysed using 1X RBC Lysis
(eBioscience, Catalog #00433357) according to the
manufacturer's protocol and removed by additional centri-
fugation. Between 105 and 1 × 106 viable bone marrow cells
were used for staining with each antibody cocktail (Supple-
mentary table 1).
All antibodies used in flow cytometry analysis were
purchased from BD Bioscience pre-conjugated with the
fluorophore.
Immunohistochemistry
At the time of harvest the liver was fixed in 10% normal
buffered formalin for 48 h, rinsed and stored in 70% ethanoluntil paraffin embedded and sectioned. Human specific
antibodies were used to detect the specific immune cells in
the dual chimeric mice. Antibodies are listed in supplemen-
tary table 1.RT-PCR
Total RNA was isolated using Trizol™ Reagent (Invitrogen,
Life Technologies) from control, liver only and liver/blood
chimeric FRGN mice. First strand cDNA synthesis was
performed using Life Technology's high capacity RNA to
cDNA™ Kit. To confirm the presence of human CD68 (hCD68)
transcripts in the dual humanized mice, PCR was performed
using AmpliTaq Gold 360 Master mix using the following
primers; hCD68 Forward primer: 5′ GCCACGGTTCATCC
AACAAGCA 3′ and hCD68 Reverse primer: 5′ CTGAGCTACA
TGGCGGTGGAG 3′. Control PCR reactions using human and
mouse specific GAPDH primers were also performed with the
same cDNAs using the following primer pairs: hGAPDH
forward: 5′ GAGAAGGCTGGGGCTCATT TGC 3′; hGAPDH
reverse: 5′ ACTGTGGCGTGATGGCCGCGG 3′; mGAPDH
forward 5′ GAGGCCGGTGCTGAGTATGTCG 3′; and mGAPDH
reverse: 5′ CAAGAAGGTGGTGAAGCAGGCA 3′. The expected
PCR products are as follows: human CD68, 376 bp, human
GAPDH, 287 bp and mouse GAPDH 531 bp.Statistics
Statistical analyses were performed using Prism 5.0d
software (GraphPad Software Inc.).
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2014.08.006.References
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